Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 10/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.36 |
| ▸ | WNT1 | P04628 | 7/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | HAT1 | O14929 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18397894 | 0.92 | LOXL2 (0.53) | LOXL2POLBGSK3BDYRK1AWNT1 | |
| SCHEMBL20438106 | 0.86 | LOXL2 (0.40) | LOXL2KMT2AGSK3BDYRK1AWNT1 | |
| SCHEMBL18397944 | 0.85 | EGLN1 (0.42) | LOXL2POLBMAPK8 | |
| SCHEMBL18397879 | 0.82 | LOXL2 (0.59) | LOXL2ABCG2ABCB1 | |
| Hydrochloric Acid SCHEMBL18397950 | 0.81 | LOXL2 (0.61) | LOXL2ABCG2ABCB1 | |
| SCHEMBL18397933 | 0.79 | LOXL2 (0.72) | LOXL2ABCG2ABCB1 | |
| SCHEMBL20438087 | 0.79 | LOXL2 (0.48) | LOXL2GSK3BDYRK1AWNT1 | |
| SCHEMBL18397868 | 0.76 | LOXL2 (0.52) | LOXL2GSK3BDYRK1AABCG2ABCB1 | |
| SCHEMBL18397914 | 0.75 | LOXL2 (0.54) | LOXL2MAPK8GSK3BDYRK1A | |
| SCHEMBL20438101 | 0.75 | P2RY14 (0.43) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215727-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-08-02 | — | — | US | disclosed |
| EP-3325462-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | Pharmakea, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017015221-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215727-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885POLB 1012/4885KMT2A 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.